While Beam Therapeutics Inc has overperformed by 2.28%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BEAM rose by 4.88%, with highs and lows ranging from $49.50 to $16.95, whereas the simple moving average jumped by 24.96% in the last 200 days.
On January 29, 2024, JP Morgan Upgraded Beam Therapeutics Inc (NASDAQ: BEAM) to Overweight. A report published by BofA Securities on December 15, 2023, Downgraded its rating to ‘Neutral’ for BEAM. Jefferies also Downgraded BEAM shares as ‘Hold’, setting a target price of $30 on the company’s shares in a report dated December 08, 2023. Leerink Partners October 20, 2023d the rating to Market Perform on October 20, 2023, and set its price target from $75 to $20. Cantor Fitzgerald October 20, 2023d its ‘Overweight’ rating to ‘Neutral’ for BEAM, as published in its report on October 20, 2023. Bernstein’s report from March 21, 2023 suggests a price prediction of $37 for BEAM shares, giving the stock a ‘Mkt Perform’ rating. Cantor Fitzgerald also rated the stock as ‘Overweight’.
Analysis of Beam Therapeutics Inc (BEAM)
Further, the quarter-over-quarter increase in sales is 1478.04%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Beam Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -15.46% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.89, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and BEAM is recording an average volume of 1.48M. On a monthly basis, the volatility of the stock is set at 7.70%, whereas on a weekly basis, it is put at 6.76%, with a loss of -2.68% over the past seven days. Furthermore, long-term investors anticipate a median target price of $48.92, showing growth from the present price of $34.84, which can serve as yet another indication of whether BEAM is worth investing in or should be passed over.
How Do You Analyze Beam Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 16.78%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 76.98% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
BEAM shares are owned by institutional investors to the tune of 76.98% at present.
